A Single-Dose, Open-Label, 3-Panel, Randomized, Pivotal Crossover Study to Assess the Bioequivalence of Darunavir When Co-Administrated With Cobicistat as Either a Fixed Dose Combination Tablet (G006) or as Single Agents Under Fed and Fasted Conditions in Healthy Subjects
Latest Information Update: 13 Aug 2015
Price :
$35 *
At a glance
- Drugs Cobicistat/darunavir (Primary) ; Cobicistat; Darunavir
- Indications HIV infections
- Focus Pharmacokinetics; Registrational
- Sponsors Janssen R&D Ireland
- 03 Jul 2013 Primary endpoint 'Time-to-peak-drug-concentration' has been met, according to the 7th International AIDS Society Conference on HIV Pathogenesis and Treatment abstract.
- 03 Jul 2013 Primary endpoint 'Peak-drug-concentration' has been met, according to the 7th International AIDS Society Conference on HIV Pathogenesis and Treatment abstract.
- 03 Jul 2013 Primary endpoint 'Area-under-the-drug-concentration-time-curve' has been met, according to the 7th International AIDS Society Conference on HIV Pathogenesis and Treatment abstract.